REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board Change

27 Sep 2023 07:00

Arix Bioscience PLC (ARIX) Board Change 27-Sep-2023 / 07:00 GMT/BST


 

 

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014

 

Arix Bioscience plc

 

Board Change

 

LONDON, 27 September 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, today announces that Robert Lyne, Chief Executive Officer has decided to step down from his position to pursue a new opportunity and will leave the company by the end of 2023.

 

Peregrine Moncreiffe, Chairman of Arix, stated:

 

“Robert has been a pivotal part of Arix’s journey and its founding purpose of bringing breakthrough advances in biotechnology to patients who need them while delivering significant returns to shareholders. He navigated the company following a period of corporate governance uncertainty, and through the Covid pandemic and subsequent market volatility, deploying a dual approach of conserving cash while enhancing value in the portfolio by selecting highly prospective new investments. This strategy has preserved shareholder value during a period of sustained market uncertainty. We thank Robert for his significant contributions to Arix over the years and wish him well in the future.

 

“Going forward, the Board’s primary focus will be to maximise shareholder returns and unlock the value in the Arix portfolio. Consequently, the Board will determine appropriate Board and management arrangements following the outcome of the strategic review and update shareholders accordingly. The Board will maintain its decision-making responsibilities on all investment decisions.”

 

[ENDS]

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

 

About Arix Bioscience plc

Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 


Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
ISIN:GB00BD045071
Category Code:BOA
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:274074
EQS News ID:1735077
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
29th Jul 20215:30 pmEQSTransaction in own shares
28th Jul 20215:30 pmEQSTransaction in own shares
27th Jul 20215:05 pmEQSTransaction in own shares
27th Jul 20217:02 amEQSArtios raises $153m in Series C financing
26th Jul 20215:00 pmEQSTransaction in own shares
23rd Jul 20215:05 pmEQSTransaction in own shares
22nd Jul 20215:07 pmEQSTransaction in own shares
21st Jul 20215:19 pmEQSTransaction in own shares
21st Jul 20217:00 amEQSNotice of Results
20th Jul 20215:14 pmEQSTransaction in own shares
19th Jul 20215:19 pmEQSTransaction in own shares
16th Jul 20215:20 pmEQSTransaction in own shares
15th Jul 20215:19 pmEQSTransaction in own shares
14th Jul 20215:08 pmEQSTransaction in own shares
14th Jul 20219:00 amEQSImara announces pricing of public offering
14th Jul 20217:00 amEQSTransaction in own shares
12th Jul 20215:33 pmEQSTransaction in own shares
8th Jul 20215:15 pmEQSTransaction in own shares
7th Jul 20215:37 pmEQSTransaction in own shares
6th Jul 20215:26 pmEQSTransaction in own shares
6th Jul 20217:01 amEQSTeam changes
5th Jul 20214:59 pmEQSTransaction in own shares
1st Jul 20215:09 pmEQSTransaction in own shares
1st Jul 20217:01 amEQSTotal Voting Rights
30th Jun 20215:00 pmEQSTransaction in own shares
29th Jun 20214:54 pmEQSTransaction in own shares
28th Jun 20215:38 pmEQSTransaction in own shares
25th Jun 20214:57 pmEQSTransaction in own shares
24th Jun 20215:21 pmEQSTransaction in own shares
23rd Jun 20215:06 pmEQSTransaction in own shares
22nd Jun 20215:18 pmEQSTransaction in own shares
21st Jun 20215:06 pmEQSTransaction in own shares
18th Jun 20215:13 pmEQSTransaction in own shares
17th Jun 20215:12 pmEQSTransaction in own shares
16th Jun 20215:25 pmEQSTransaction in own shares
15th Jun 20215:40 pmEQSTransaction in own shares
14th Jun 20215:20 pmEQSTransaction in own shares
14th Jun 20212:55 pmEQSResults of Annual General Meeting
11th Jun 20215:01 pmEQSTransaction in own shares
11th Jun 20211:05 pmEQSClinical portfolio update
10th Jun 20215:26 pmEQSTransaction in own shares
9th Jun 20215:15 pmEQSTransaction in own shares
8th Jun 20215:14 pmEQSTransaction in own shares
7th Jun 20215:08 pmEQSTransaction in own shares
4th Jun 20215:13 pmEQSTransaction in own shares
4th Jun 20213:25 pmEQSHarpoon presents updated interim clinical data for HPN424 at the 2021 ASCO Annual Meeting
3rd Jun 20215:34 pmEQSTransaction in own shares
2nd Jun 20215:12 pmEQSTransaction in own shares
1st Jun 20215:35 pmEQSTransaction in own shares
1st Jun 20217:01 amEQSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.